Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Paclitaxel + Pemetrexed & Non-small-cell lung carcinoma (NSCLC), Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Paclitaxel + Pemetrexed is approved as first‑line treatment in metastatic/recurrent Non-small-cell lung cancer (NSCLC) (2)
The Nivolumab/Ipilimumab EU product information similarly includes first‑line metastatic Non-small-cell lung cancer (NSCLC) in combination with two cycles of platinum‑based chemotherapy, with [pemetrexed](brain://pTvWJLE4iEudPmnrIlsuSQ/…